总的来说，本研究建立了肥胖、衰老以及肿瘤之间的关联，证明了肥胖通过诱发细胞衰老而促进肿瘤进展。此外还发现并论证了抗衰老药物ABT-263对于肥胖肿瘤患者的潜在治疗价值。

这些结果一方面为肥胖患者、尤其是难以从当前免疫治疗中获益的低免疫原性肿瘤患者，提供了治疗新方案；另外也提示我们在未来的肿瘤诊治中，患者体重指数可作为治疗药物选择的重要依据。当然，这些结果的推广还有赖于进一步临床试验的验证。

参考文献：

[1] Avgerinos KI, Spyrou N, Mantzoros CS, et al. Obesity and cancer risk: Emerging biological mechanisms and perspectives[J]. Metabolism, 2019, 92:121-135. DOI:10.1016/j.metabol.2018.11.001.

[2] Kolb R, Sutterwala FS,Zhang W. Obesity and cancer: inflammation bridges the two[J]. Curr Opin Pharmacol, 2016, 29:77-89. DOI:10.1016/j.coph.2016.07.005.

[3] Mu oz-Esp n D,Serrano M. Cellular senescence: from physiology to pathology[J]. Nat Rev Mol Cell Biol, 2014, 15 (7):482-496. DOI:10.1038/nrm3823.

[4] Tchkonia T, Morbeck DE, Von Zglinicki T, et al. Fat tissue, aging, and cellular senescence[J]. Aging Cell, 2010, 9 (5):667-684. DOI:10.1111/j.1474-9726.2010.00608.x.

[5] Fournier F, Diaz-Marin R, Pilon F, et al. Obesity triggers tumoral senescence and renders poorly immunogenic malignancies amenable to senolysis[J]. Proc Natl Acad Sci U S A, 2023, 120 (1):e2209973120. DOI:10.1073/pnas.2209973120.

[6] Prata L, Ovsyannikova IG, Tchkonia T, et al. Senescent cell clearance by the immune system: Emerging therapeutic opportunities[J]. Semin Immunol, 2018, 40:101275. DOI:10.1016/j.smim.2019.04.003.

[7] Chang J, Wang Y, Shao L, et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice[J]. Nat Med, 2016, 22 (1):78-83. DOI:10.1038/nm.4010.

[8] Gandhi L, Camidge DR, Ribeiro de Oliveira M, et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors[J]. J Clin Oncol, 2011, 29 (7):909-916. DOI:10.1200/jco.2010.31.6208.

[9] Wilson WH, O Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity[J]. Lancet Oncol, 2010, 11 (12):1149-1159. DOI:10.1016/s1470-2045(10)70261-8.

[10] Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease[J]. J Clin Oncol, 2012, 30 (5):488-496. DOI:10.1200/jco.2011.34.7898.